Almac Sciences Invest In Edinburgh Facility
March 8, 2007
New half million pound investment will lead to eight new jobs in Elvingston
Almac Sciences has supported drug discovery, development and commercialisation through contract R&D, custom manufacturing and analytical services, since 1992. The service package has been steadily developed to include speciality offerings in cytotoxic and potent manufacturing; peptides, protein and oligo synthesis, chirals and radiolabelling.
The latest development is expansion of the division’s analytical services offering at its Elvingston facility, outside Edinburgh, with the addition of eight extra staff. The half million pound investment means there is now 27 staff employed at the laboratory in Elvingston. The new additional facilities were fully operational at the end of February 2007.
The investment, in the Analytical Services unit of Almac Sciences, will expand the company’s operations in bioanalysis, characterisation, stability testing, structure confirmation and batch release.
Head of Analytical Operations, Jon Cook said:
“The setting up of this new laboratory is an exciting opportunity. Across all divisions, our company is growing from strength to strength, and this investment is part of our overall growth strategy and ensures that we have the full capability to manage our customer requirements.”
Dr. Rosaleen McGuckin, VP Business Development at Almac Sciences said:
“These new services complement the existing service operations within Almac Sciences, as well as across the Almac Group. With Almac’s unique business model, we will be the leader in the generation of superior solutions for the advancement of human health.”
02890 339949 / 017841 970678
Notes for Editors:
Almac Sciences is part of the Almac Group, which comprises five closely integrated divisions offering a broad range of services from R&D, diagnostic/genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors.
Almac Sciences operates from a £25m 80,000 sq. ft. HQ and laboratory complex in Craigavon, Northern Ireland, with a production and R&D center near Edinburgh, Scotland. The business has over 200 employees, including 120 scientists.